Sensorion, a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing disorders, announces preliminary safety results from NOTOXIS, its Phase 2a Proof of Concept clinical trial of SENS-401 in patients suffering from Cisplatin-Induced Ototoxicity.
